Kiora Pharmaceuticals (KPRX) Competitors $3.00 -0.01 (-0.33%) Closing price 04:00 PM EasternExtended Trading$3.02 +0.02 (+0.50%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock KPRX vs. ELYM, XLO, ATHE, LVTX, LTRN, CLNN, RNTX, KZR, OKUR, and ESLAShould you be buying Kiora Pharmaceuticals stock or one of its competitors? The main competitors of Kiora Pharmaceuticals include Eliem Therapeutics (ELYM), Xilio Therapeutics (XLO), Alterity Therapeutics (ATHE), LAVA Therapeutics (LVTX), Lantern Pharma (LTRN), Clene (CLNN), Rein Therapeutics (RNTX), Kezar Life Sciences (KZR), OnKure Therapeutics (OKUR), and Estrella Immunopharma (ESLA). These companies are all part of the "pharmaceutical products" industry. Kiora Pharmaceuticals vs. Its Competitors Eliem Therapeutics Xilio Therapeutics Alterity Therapeutics LAVA Therapeutics Lantern Pharma Clene Rein Therapeutics Kezar Life Sciences OnKure Therapeutics Estrella Immunopharma Kiora Pharmaceuticals (NASDAQ:KPRX) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability, earnings and media sentiment. Does the media favor KPRX or ELYM? In the previous week, Kiora Pharmaceuticals had 2 more articles in the media than Eliem Therapeutics. MarketBeat recorded 2 mentions for Kiora Pharmaceuticals and 0 mentions for Eliem Therapeutics. Kiora Pharmaceuticals' average media sentiment score of 0.93 beat Eliem Therapeutics' score of 0.00 indicating that Kiora Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Kiora Pharmaceuticals Positive Eliem Therapeutics Neutral Do analysts rate KPRX or ELYM? Kiora Pharmaceuticals currently has a consensus target price of $10.00, suggesting a potential upside of 233.33%. Given Kiora Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Kiora Pharmaceuticals is more favorable than Eliem Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiora Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders hold more shares of KPRX or ELYM? 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are owned by institutional investors. 0.1% of Kiora Pharmaceuticals shares are owned by company insiders. Comparatively, 4.7% of Eliem Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more volatility & risk, KPRX or ELYM? Kiora Pharmaceuticals has a beta of -0.66, indicating that its stock price is 166% less volatile than the S&P 500. Comparatively, Eliem Therapeutics has a beta of -0.39, indicating that its stock price is 139% less volatile than the S&P 500. Is KPRX or ELYM more profitable? Kiora Pharmaceuticals' return on equity of -42.82% beat Eliem Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kiora PharmaceuticalsN/A -42.82% -32.18% Eliem Therapeutics N/A -47.03%-45.97% Which has preferable valuation & earnings, KPRX or ELYM? Kiora Pharmaceuticals has higher revenue and earnings than Eliem Therapeutics. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Kiora Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKiora Pharmaceuticals$16.02M0.57$3.60M-$2.90-1.03Eliem TherapeuticsN/AN/A-$35.12M-$0.53-2.55 SummaryKiora Pharmaceuticals beats Eliem Therapeutics on 10 of the 13 factors compared between the two stocks. Get Kiora Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KPRX vs. The Competition Export to ExcelMetricKiora PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.16M$2.45B$5.61B$9.11BDividend YieldN/A1.79%5.24%4.01%P/E RatioN/A3.9119.7619.92Price / Sales0.57729.02430.8999.65Price / Cash2.43165.3637.4658.16Price / Book0.354.608.045.49Net Income$3.60M$31.26M$3.18B$250.27M7 Day Performance4.75%4.80%3.72%4.78%1 Month Performance-5.06%4.19%3.72%7.20%1 Year Performance-29.08%-2.89%29.92%17.27% Kiora Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KPRXKiora Pharmaceuticals3.2192 of 5 stars$3.00-0.3%$10.00+233.3%-31.1%$9.16M$16.02M0.0010Positive NewsELYMEliem TherapeuticsN/A$1.18-6.3%N/A-81.2%$35.11MN/A-2.239High Trading VolumeXLOXilio Therapeutics2.9585 of 5 stars$0.68+0.7%$4.00+488.3%-22.5%$34.97M$6.34M-0.8170Positive NewsATHEAlterity Therapeutics2.2595 of 5 stars$4.09+4.1%$12.00+193.4%+101.6%$34.88MN/A0.0010Gap UpTrading HaltedLVTXLAVA Therapeutics1.4492 of 5 stars$1.32+0.8%$3.17+139.9%-29.3%$34.46M$11.98M-1.2760LTRNLantern Pharma3.1487 of 5 stars$3.16-0.9%$25.00+691.1%-15.0%$34.40MN/A-1.7220Positive NewsCLNNClene3.5857 of 5 stars$3.91+4.0%$40.00+923.0%-33.1%$33.78M$340K-0.97100News CoverageRNTXRein TherapeuticsN/A$1.40-4.8%N/AN/A$32.57MN/A-0.499High Trading VolumeKZRKezar Life Sciences4.2834 of 5 stars$4.58+3.2%$39.50+762.4%-15.6%$32.44M$7M-0.4260Positive NewsOKUROnKure Therapeutics3.5874 of 5 stars$2.39-0.4%$32.33+1,252.9%N/A$32.42MN/A-0.45N/AESLAEstrella Immunopharma3.1734 of 5 stars$0.96+9.0%$16.00+1,566.7%-28.9%$31.86MN/A-3.69N/A Related Companies and Tools Related Companies Eliem Therapeutics Competitors Xilio Therapeutics Competitors Alterity Therapeutics Competitors LAVA Therapeutics Competitors Lantern Pharma Competitors Clene Competitors Rein Therapeutics Competitors Kezar Life Sciences Competitors OnKure Therapeutics Competitors Estrella Immunopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KPRX) was last updated on 7/11/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiora Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiora Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
